MYD88 mutations have higher prevalence in cases with extranodal localization and mediate active BCR signaling phenotype within the MCD genotype of DLBCL [3,56,58,126,127,130,163,164,165]. Here, BCR is linked to diffuse large B-cell lymphoma.